PDF(Pubmed)
Abstract：
UNASSIGNED: Ahiflower oil from the seeds of Buglossoides arvensis is rich in α-linolenic acid (ALA) and stearidonic acid (SDA). ALA and SDA are potential precursor fatty acids for the endogenous synthesis of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are n3-long chain polyunsaturated fatty acids (n3-LC-PUFAS), in humans. Since taurine, an amino sulfonic acid, is often associated with tissues rich in n3-LC-PUFAS (e.g., in fatty fish, human retina), taurine may play a role in EPA- and DHA-metabolism.
UNASSIGNED: To examine the capacity of the plant-derived precursor fatty acids (ALA and SDA) and of the potential fatty acid metabolism modulator taurine to increase n3-LC-PUFAS and their respective oxylipins in human plasma and cultivated hepatocytes (HepG2 cells).
UNASSIGNED: In a monocentric, randomized crossover study 29 healthy male volunteers received three sequential interventions, namely ahiflower oil (9 g/day), taurine (1.5 g/day) and ahiflower oil (9 g/day) + taurine (1.5 g/day) for 20 days. In addition, cultivated HepG2 cells were treated with isolated fatty acids ALA, SDA, EPA, DHA as well as taurine alone or together with SDA.
UNASSIGNED: Oral ahiflower oil intake significantly improved plasma EPA levels (0.2 vs. 0.6% of total fatty acid methyl esters (FAMES)) in humans, whereas DHA levels were unaffected by treatments. EPA-levels in SDA-treated HepG2 cells were 65% higher (5.1 vs. 3.0% of total FAMES) than those in ALA-treated cells. Taurine did not affect fatty acid profiles in human plasma in vivo or in HepG2 cells in vitro. SDA-rich ahiflower oil and isolated SDA led to an increase in EPA-derived oxylipins in humans and in HepG2 cells, respectively.
UNASSIGNED: The consumption of ahiflower oil improves the circulating levels of EPA and EPA-derived oxylipins in humans. In cultivated hepatocytes, EPA and EPA-derived oxylipins are more effectively increased by SDA than ALA.
UNASSIGNED: To examine the capacity of the plant-derived precursor fatty acids (ALA and SDA) and of the potential fatty acid metabolism modulator taurine to increase n3-LC-PUFAS and their respective oxylipins in human plasma and cultivated hepatocytes (HepG2 cells).
UNASSIGNED: In a monocentric, randomized crossover study 29 healthy male volunteers received three sequential interventions, namely ahiflower oil (9 g/day), taurine (1.5 g/day) and ahiflower oil (9 g/day) + taurine (1.5 g/day) for 20 days. In addition, cultivated HepG2 cells were treated with isolated fatty acids ALA, SDA, EPA, DHA as well as taurine alone or together with SDA.
UNASSIGNED: Oral ahiflower oil intake significantly improved plasma EPA levels (0.2 vs. 0.6% of total fatty acid methyl esters (FAMES)) in humans, whereas DHA levels were unaffected by treatments. EPA-levels in SDA-treated HepG2 cells were 65% higher (5.1 vs. 3.0% of total FAMES) than those in ALA-treated cells. Taurine did not affect fatty acid profiles in human plasma in vivo or in HepG2 cells in vitro. SDA-rich ahiflower oil and isolated SDA led to an increase in EPA-derived oxylipins in humans and in HepG2 cells, respectively.
UNASSIGNED: The consumption of ahiflower oil improves the circulating levels of EPA and EPA-derived oxylipins in humans. In cultivated hepatocytes, EPA and EPA-derived oxylipins are more effectively increased by SDA than ALA.
摘要：
■来自罗格罗西的种子的葵花籽油富含α-亚麻酸（ALA）和十八碳四烯酸（SDA）。ALA和SDA是内源性合成二十碳五烯酸（EPA）和二十二碳六烯酸（DHA）的潜在前体脂肪酸，它们是n3-长链多不饱和脂肪酸（n3-LC-PUFAS），在人类中。因为牛磺酸,氨基磺酸，通常与富含n3-LC-PUFAS的组织相关(例如，在脂肪鱼，人类视网膜)，牛磺酸可能在EPA和DHA代谢中起作用。
为了检查植物衍生的前体脂肪酸(ALA和SDA)和潜在的脂肪酸代谢调节剂牛磺酸增加人血浆和培养的肝细胞(HepG2细胞)中n3-LC-PUFAS和它们各自的氧化脂素的能力。
■在单中心，随机交叉研究29名健康男性志愿者接受了三项序贯干预，即葵花籽油（9克/天），牛磺酸（1.5克/天）和葵花籽油（9克/天）+牛磺酸（1.5克/天）20天。此外,培养的HepG2细胞用分离的脂肪酸ALA处理，SDA,EPA,DHA以及牛磺酸单独或与SDA一起。
■口服葵花籽油摄入显着改善了血浆EPA水平（0.2vs.人类总脂肪酸甲酯(FAMES)的0.6%，而DHA水平不受治疗的影响。SDA处理的HepG2细胞中的EPA水平高65％（5.1与总FAMES的3.0%)比ALA处理的细胞高。牛磺酸不影响体内人血浆或体外HepG2细胞中的脂肪酸谱。富含SDA的葵花籽油和分离的SDA导致人和HepG2细胞中EPA衍生的氧化脂素增加，分别。
■食用葵花籽油改善了EPA和EPA衍生的氧脂素在人体中的循环水平。在培养的肝细胞中，EPA和EPA衍生的氧化脂素被SDA比ALA更有效地增加。
为了检查植物衍生的前体脂肪酸(ALA和SDA)和潜在的脂肪酸代谢调节剂牛磺酸增加人血浆和培养的肝细胞(HepG2细胞)中n3-LC-PUFAS和它们各自的氧化脂素的能力。
■在单中心，随机交叉研究29名健康男性志愿者接受了三项序贯干预，即葵花籽油（9克/天），牛磺酸（1.5克/天）和葵花籽油（9克/天）+牛磺酸（1.5克/天）20天。此外,培养的HepG2细胞用分离的脂肪酸ALA处理，SDA,EPA,DHA以及牛磺酸单独或与SDA一起。
■口服葵花籽油摄入显着改善了血浆EPA水平（0.2vs.人类总脂肪酸甲酯(FAMES)的0.6%，而DHA水平不受治疗的影响。SDA处理的HepG2细胞中的EPA水平高65％（5.1与总FAMES的3.0%)比ALA处理的细胞高。牛磺酸不影响体内人血浆或体外HepG2细胞中的脂肪酸谱。富含SDA的葵花籽油和分离的SDA导致人和HepG2细胞中EPA衍生的氧化脂素增加，分别。
■食用葵花籽油改善了EPA和EPA衍生的氧脂素在人体中的循环水平。在培养的肝细胞中，EPA和EPA衍生的氧化脂素被SDA比ALA更有效地增加。
